Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Isoquercetin to Reduce Thrombin Generation in Ovarian Cancer
NCT07303894Phase 2Recruiting
- Sponsor
- Memorial Sloan Kettering Cancer Center
- Start
- Jan 2026
- Primary completion
- Jan 2032
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of isoquercetin in venous thromboembolism (VTE), sponsored by Memorial Sloan Kettering Cancer Center. Started Jan 2026; status: recruiting.
02
Drugs
isoquercetin
03
Conditions
venous thromboembolism (VTE)
Beyond the preview
Go deeper on NCT07303894.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07303894.